FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320512253> ?p ?o ?g. }

• W2320512253 abstract "Background: Neutropenic complications including severe and febrile neutropenia (FN) represent major dose-limiting toxicities of cancer chemotherapy. A general risk model for neutropenic complications across major solid tumors has been developed and validated (Lyman et al. Cancer 2011). Current guidelines recommend consideration of primary prophylaxis with a colony-stimulating factor (CSF) in patients at >20% risk of FN. The decision for primary CSF prophylaxis in patients on intermediate risk chemotherapy (10-20%) is based on physician assessment of individual patient risk factors for FN. This study assesses the ability of this general FN risk model to identify ESBC patients on intermediate risk chemotherapy who are at a personal high risk for developing a neutropenic complication. Methods: A prospective cohort study accrued 4458 consenting patients starting a new chemotherapy regimen at 115 randomly selected community oncology practices throughout the United States from 2002–2006. The risk of severe or febrile neutropenia (SNFN) in cycle 1 and across 4 cycles was estimated [±95% CI] utilizing logistic regression analysis and adjusting for key clinical factors including among others: age, prior chemotherapy, abnormal hepatic or renal function, low pretreatment white blood count, immunosuppressive medications, CSF prophylaxis, and planned relative dose intensity as well as major chemotherapeutic agents. The cumulative risk of FN across 4 cycles was also estimated by the product limit method of Kaplan and Meier. Results: Among 1224 patients with ESBC, 822 received intermediate risk chemotherapy based on National Comprehensive Cancer Network guidelines. Among these patients, cycle 1 SNFN occurred in 37%, at least one episode of FN over 4 cycles of chemotherapy in 17%, with 15% receiving primary CSF prophylaxis. The predicted risk of cycle 1 SNFN ranged from 1%-79%, with mean (median) risk of 33.8% (39.0%). Model performance was good with a c-statistic of 0.73 [0.69−0.76]. Based on this general FN risk model, cycle 1 SNFN occurred in 47% of predicted high risk ESBC patients [42 — 52%] compared to 13% [8-17%] of low risk patients. One or more FN events over 4 cycles occurred in 20% [17-24%] of predicted high risk versus 10% [6-14%] in low risk patients. The cumulative risk of FN by Kaplan-Meier estimation was 23% in high risk and 10% in low risk patients. Model sensitivity and specificity for FN were 83% and 33%, respectively. The majority of SNFN (76%) and FN (58%) events among high risk patients occurred in cycle 1. 50% of high risk patients who did not receive primary CSF prophylaxis went on to receive CSF during subsequent cycles. Conclusions: Based on good test performance characteristics, this clinical FN prediction model also identifies ESBC patients receiving intermediate risk chemotherapy at high personal risk for FN (FN >20%) over the first 4 cycles of chemotherapy. Half of predicted high risk patients without primary CSF prophylaxis will be given CSF in subsequent cycles after the occurrence of a neutropenic complication. This also confirms previous clinical trial findings that the majority of febrile neutropenic events occur in the first cycle. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-20-03." @default.
• W2320512253 created "2016-06-24" @default.
• W2320512253 creator A5005999776 @default.
• W2320512253 creator A5011930018 @default.
• W2320512253 creator A5062529227 @default.
• W2320512253 creator A5070262118 @default.
• W2320512253 creator A5080453001 @default.
• W2320512253 creator A5090143035 @default.
• W2320512253 date "2011-12-15" @default.
• W2320512253 modified "2023-09-25" @default.
• W2320512253 title "P5-20-03: Personalizing Supportive Care: A Clinical Prediction Model for Neutropenic Complications in Patients with Early-Stage Breast Cancer (ESBC) Receiving Intermediate Risk Chemotherapy." @default.
• W2320512253 doi "https://doi.org/10.1158/0008-5472.sabcs11-p5-20-03" @default.
• W2320512253 hasPublicationYear "2011" @default.
• W2320512253 type Work @default.
• W2320512253 sameAs 2320512253 @default.
• W2320512253 citedByCount "1" @default.
• W2320512253 countsByYear W23205122532015 @default.
• W2320512253 crossrefType "proceedings-article" @default.
• W2320512253 hasAuthorship W2320512253A5005999776 @default.
• W2320512253 hasAuthorship W2320512253A5011930018 @default.
• W2320512253 hasAuthorship W2320512253A5062529227 @default.
• W2320512253 hasAuthorship W2320512253A5070262118 @default.
• W2320512253 hasAuthorship W2320512253A5080453001 @default.
• W2320512253 hasAuthorship W2320512253A5090143035 @default.
• W2320512253 hasConcept C121608353 @default.
• W2320512253 hasConcept C126322002 @default.
• W2320512253 hasConcept C141071460 @default.
• W2320512253 hasConcept C143998085 @default.
• W2320512253 hasConcept C2776694085 @default.
• W2320512253 hasConcept C2777063308 @default.
• W2320512253 hasConcept C2778336483 @default.
• W2320512253 hasConcept C2778850193 @default.
• W2320512253 hasConcept C2781413609 @default.
• W2320512253 hasConcept C530470458 @default.
• W2320512253 hasConcept C71924100 @default.
• W2320512253 hasConceptScore W2320512253C121608353 @default.
• W2320512253 hasConceptScore W2320512253C126322002 @default.
• W2320512253 hasConceptScore W2320512253C141071460 @default.
• W2320512253 hasConceptScore W2320512253C143998085 @default.
• W2320512253 hasConceptScore W2320512253C2776694085 @default.
• W2320512253 hasConceptScore W2320512253C2777063308 @default.
• W2320512253 hasConceptScore W2320512253C2778336483 @default.
• W2320512253 hasConceptScore W2320512253C2778850193 @default.
• W2320512253 hasConceptScore W2320512253C2781413609 @default.
• W2320512253 hasConceptScore W2320512253C530470458 @default.
• W2320512253 hasConceptScore W2320512253C71924100 @default.
• W2320512253 hasLocation W23205122531 @default.
• W2320512253 hasOpenAccess W2320512253 @default.
• W2320512253 hasPrimaryLocation W23205122531 @default.
• W2320512253 hasRelatedWork W1909026420 @default.
• W2320512253 hasRelatedWork W1971513046 @default.
• W2320512253 hasRelatedWork W2026417873 @default.
• W2320512253 hasRelatedWork W2057655957 @default.
• W2320512253 hasRelatedWork W2083035728 @default.
• W2320512253 hasRelatedWork W2128830492 @default.
• W2320512253 hasRelatedWork W2313971080 @default.
• W2320512253 hasRelatedWork W2317582407 @default.
• W2320512253 hasRelatedWork W2543518004 @default.
• W2320512253 hasRelatedWork W2574201053 @default.
• W2320512253 hasRelatedWork W2588945616 @default.
• W2320512253 hasRelatedWork W2605037379 @default.
• W2320512253 hasRelatedWork W2807063093 @default.
• W2320512253 hasRelatedWork W2892571161 @default.
• W2320512253 hasRelatedWork W2894230777 @default.
• W2320512253 hasRelatedWork W2963563988 @default.
• W2320512253 hasRelatedWork W2967413449 @default.
• W2320512253 hasRelatedWork W3009779957 @default.
• W2320512253 hasRelatedWork W3083763733 @default.
• W2320512253 hasRelatedWork W652352161 @default.
• W2320512253 isParatext "false" @default.
• W2320512253 isRetracted "false" @default.
• W2320512253 magId "2320512253" @default.
• W2320512253 workType "article" @default.